In: Journal of Infectious Diseases, 2010, vol. 201, no. Supplement_1, p. S73-S77
|
In: The Journal of Infectious Diseases, 2009, vol. 200, no. 11, p. 1746-1754
|
In: Clinical Infectious Diseases, 2012, vol. 55, no. 10, p. 1408-1416
|
In: Clinical Infectious Diseases, 2011, vol. 52, no. 10, p. 1257-1266
|
In: Clinical Infectious Diseases, 2009, vol. 49, no. 4, p. 626-635
|
In: The Journal of Infectious Diseases, 2013, vol. 208, no. 7, p. 1102-1112
|
In: The Journal of Infectious Diseases, 2010, vol. 201, no. 12, p. 1788-1795
|
In: Journal of Antimicrobial Chemotherapy, 2009, vol. 64, no. 6, p. 1126-1129
|
In: International Journal of Epidemiology, 2012, vol. 41, no. 2, p. 433-445
|
In: Neurology, 2013, vol. 80, no. 6, p. 553–560
Objective: To assess the efficacy and safety of rivastigmine for the treatment of HIV-associated neurocognitive disorders (HAND) in a cohort of long-lasting aviremic HIV+ patients.Methods: Seventeen aviremic HIV+ patients with HAND were enrolled in a randomized, double-blind, placebo-controlled, crossover study to receive either oral rivastigmine (up to 12 mg/day for 20 weeks) followed by placebo...
|